First-in-human cancer trials delivering translational innovation
New targets displaced validated mechanisms in first-in-human abstracts at ASCO 2022
The clinical oncology pipeline is moving in an innovative direction, with new targets, next-generation technologies and biomarker-driven development programs displacing established mechanisms in this year’s crop of first-in-human studies presented at ASCO.
BioCentury’s analysis of the first-in-human abstracts presented at the American Society of Clinical Oncology (ASCO) conference last week provides a snapshot of translational trends for therapies entering the oncology pipeline. ...
BCIQ Company Profiles